Hematopoietic cell transplantation (HCT) provides a life-prolonging or potentially curative treatment option for patients with hematologic malignancies. Given the high transplant-related morbidity, these treatment strategies were initially restricted to younger patients, but are increasingly being used in older adults. The incidence of most hematologic malignancies increases with age; with the aging of the population, the number of potential older candidates for HCT increases. Autologous HCT (auto-HCT) in older patients may confer a slightly increased risk of specific toxicities (such as cardiac toxicities and mucositis) and have modestly lower effectiveness (in the case of lymphoma). However, auto-HCT remains a feasible, safe, and effective therapy for selected older adults with multiple myeloma and lymphoma. Similarly, allogeneic transplant (allo-HCT) is a potential therapeutic option for selected older adults, although fewer data exist on allo-HCT in older patients. Based on currently available data, age alone is not the best predictor of toxicity and outcomes; rather, the comorbidities and functional status of the older patient are likely better predictors of toxicity than chronologic age in both the autologous and allogeneic setting. A comprehensive geriatric assessment (CGA) in older adults being considered for either an auto-HCT or allo-HCT may identify additional problems or geriatric syndromes, which may not be detected during the standard pretransplant evaluation. Further research is needed to establish the utility of CGA in predicting toxicity and to evaluate the quality of survival in older adults undergoing HCT. (J Natl Compr Canc Netw 2014;12:128-136) 
The incidence of most hematologic malignancies increases with age. [1] [2] [3] With the aging of the population, a disproportionate increase in the number of older adults diagnosed with hematologic malignancies is looming. 4 Aging is associated with a greater prevalence of impaired functional status 3 and comorbid medical conditions. 5 However, the aging process is heterogeneous, and chronologic age alone does not adequately reflect the health status of an older individual.
Hematopoietic cell transplant (HCT) provides a potentially life-prolonging or curative option for many patients with hematologic malignancies, and with greater experience and improved supportive care, physicians are increasingly referring older adults for this procedure. The Center for International Blood and Marrow Transplant Research has recorded a significant increase in the number of older adults undergoing autologous (auto-HCT) or allogeneic transplant (allo-HCT). In 1994-1995, fewer than 1% of patients who underwent auto-HCTs were aged 70 years or older; in [2004] [2005] , this percentage increased to 5%. 6 The percentage of auto-HCTs performed in patients aged 60 to 69 increased even more precipitously during that period, from 6% to 25%. The same trend has been seen with allo-HCT: between 1994 and 2005, the number of patients older than 60 years who underwent allo-HCT increased 13-fold. 7 This trend of increasing numbers of older adults undergoing HCT will likely continue, because of an increasing number of older patients being diagnosed with hematologic malignancies. Thus, a detailed examination of the evidence regarding the use of auto-HCT and allo-HCT in older adults is relevant and timely. This article discusses the available data regarding the feasibility, tolerability, toxicity, and effectiveness of auto-HCT and allo-HCT in older adults (Table 1) , and reviews the role of comprehensive geriatric assessment (CGA), which can be used to globally evaluate the functional status, comorbidities, medications, cognition, nutritional status, psychological state, and social support of older adults who may be candidates for HCT. Finally, the limitations of the currently available data on HCT in older adults are described, and opportunities are identified for future research to fill in these knowledge gaps and improve the care of older adults with hematologic malignancies.
Auto-HCT
Auto-HCT may be used as part of initial therapy or after relapse in older adults with several hematologic malignancies. The available data on auto-HCT in older adults are limited; studies are largely retrospective and examine highly selected groups of patients. With these caveats in mind, stem cell mobilization, engraftment, tolerability, and efficacy among older adults undergoing auto-HCT appear overall to be similar to those among younger adults, with the exceptions that are discussed in this section.
Stem Cell Mobilization
Preclinical models confirm substantial changes in aged hematopoietic stem and progenitor cells, with reduced engraftment and homing function, altered cell-surface proteins and transcriptional activity, and accumulating DNA damage. 8 These changes may underlie clinical differences in hematopoietic cell mobilization between older and younger patients. Older patients with myeloma tend to mobilize fewer total progenitor or CD34 + cells/kg, and require more apheresis procedures to collect adequate numbers of cells. 9 In a large cohort study of all patients with multiple myeloma undergoing mobilization, age was independently associated with poor collection (defined as ≤1 x 10 6 CD34 + cells/kg/d), although 92% of older patients were able to collect adequate stem cells to proceed with a single auto-HCT. 10 Among older adults with lymphoma, stem cell harvest is feasible and as successful as in younger patients. 11, 12 Plerixafor, the CXCR4 antagonist, provides a promising chemotherapy-free mobilization regimen that improves the rates of successful mobilization in older adults with myeloma and lymphoma over granulocyte colony-stimulating factor alone.
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Toxicity of Auto-HCT
Early restriction of the use of auto-HCT to younger adults undoubtedly stemmed from concerns about increased risk of toxicity for older patients. Several studies have now shown that selected older adults with myeloma have similar time to neutrophil or platelet engraftment as younger patients and can tolerate auto-HCT without a substantially increased risk of toxicity. [14] [15] [16] Nevertheless, some specific toxicities may occur with greater frequency among older patients with myeloma undergoing auto-HCT. For example, older adults may experience greater risk of cardiac toxicity (50% vs 10%; P<.0001), 17 arrhythmia (8% vs 0%; P=.02), 18 and oral/ CE gastrointestinal toxicity (45% vs 23%; P=.06) 16 after auto-HCT. However, these age-related increases in toxicities have not been reported across all studies, and, in one report, older adults actually had less nausea than their younger counterparts (5% vs 18%; P=.007). 17 Similarly, among older adults with lymphoma who undergo auto-HCT, some complications, such as nausea, mucositis, cardiovascular events (eg, atrial fibrillation), and neurologic complications may be more frequent, however, not all studies have consistently shown an increased risk for these complications. 17, [19] [20] [21] Infections, sinusoidal obstruction syndrome (formerly veno-occlusive disease), and pneumonitis, which were major concerns in earlier studies, [22] [23] [24] are not more frequent in recent studies of older patients with lymphoma. 17, [19] [20] [21] Moreover, time to neutrophil engraftment, antibiotic use, and length of hospitalization are similar for younger and older patients undergoing auto-HCT for lymphoma. 17, [19] [20] [21] One notable exception is platelet count recovery, which may be slightly delayed in older patients with lymphoma.
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Treatment-Related Mortality of Auto-HCT
Early studies suggested that older adults undergoing auto-HCT were at greater risk for transplant-related complications and treatment-related mortality (TRM). [22] [23] [24] Several large retrospective studies estimated the 1-year TRM for older patients (age ≥55 years) to be 25% to 38%. [22] [23] [24] However, these older studies frequently included patients who were conditioned with high-dose total body irradiation (TBI), which has been associated with TRM as high as 60% in older patients. 22 Moreover, the older studies did not examine the impact of comorbidities, rather than age, on TRM.
With the adoption of better supportive care and reduction in the use of TBI-based conditioning, TRM rates for older adults undergoing auto-HCT have substantially improved. Recent studies report 1-year TRM rates for older patients (age ≥55 years) of 4% to 12%, which are similar or slightly higher than those reported for younger patients. 17, 19, 20, [25] [26] [27] [28] [29] In addition, the same risk factors associated with increased TRM in younger adults remain informative for older adults: poor performance status, 27, 28 high comorbidity index, 19 multiple prior therapies, 27, 29 and advanced or chemotherapy-resistant disease. 27, 28 Subgroups of older patients may continue to have a modestly higher TRM than their younger counter- 
Auto-HCT
• Few studies exist evaluating the efficacy of auto-HCT in patients older than 65 years; essentially no studies exist that evaluate auto-HCT in patients older than 75 years.
• Available data are primarily derived from retrospective studies of selected patients that may be subject to intrinsic biases associated with these analyses; most studies were confined to patients with multiple myeloma and/or lymphoma.
• Older adults are able to mobilize adequate numbers of stem cells for auto-HCT.
• Comorbidity risk factors associated with poor outcomes in younger adults are also informative for older adults.
• Conditioning regimens containing ablative total body irradiation are associated with a higher TRM for adults older than 65 years.
• Older adults may display a modestly higher risk for specific toxicities and TRM, but older adults tolerate the procedure reasonably well.
• Older adults with specific types of malignancies may have a slightly higher risk of relapse, but auto-HCT displays a similar effectiveness in older adults as in younger adults.
• Large prospective studies are needed to evaluate the efficacy of auto-HCT for adults older than 65 years.
Allo-HCT
• Retrospective studies suggest that selected older adults with MDS undergoing an allo-HCT experience no increase in TRM; data in patients older than 75 years are extremely limited.
• Among participants in a clinical trial of adults aged 60 to 75 years with acute myeloid leukemia, MDS, chronic lymphocytic leukemia, lymphoma, and multiple myeloma, age was not associated with nonrelapse mortality, progression-free survival, or overall survival; comorbidities were prognostic.
parts. One study reported that older patients with advanced follicular or high-grade lymphoma had a significantly higher 5-year TRM than their younger counterparts (15% vs 9%), even after adjusting for other potential prognostic factors. 28 Thus, when considering the potential TRM for older adults, patients must be carefully evaluated to determine how medically fit they are to undergo auto-HCT.
The previously described studies were primarily retrospective in nature. In addition, the evaluated patients were relatively heterogeneous, including various types and stages of hematologic malignancies, and a variety of different conditioning regimens. Moreover, most analyses used age cutoffs between 55 and 60 years to denote "older" patients. Two relatively small retrospective studies described the feasibility of auto-HCT for patients with lymphoma aged 69 years and older, 30, 31 which represents the age group frequently afflicted by this malignancy. For this patient population, the 1-year nonrelapse mortality (NRM) rate may be significantly higher than that in patients aged 65 to 69 years (35% vs 8%; P=.0017), with a higher proportion of deaths attributable to infection in the older group. 31 Certainly, the limited numbers of patients and retrospective nature of these analyses require cautious interpretation and may not be generalizable to other patients older than 69 years. Similarly, data on patients with multiple myeloma older than 70 years are sparse. In one series of 84 patients older than 70 years who underwent auto-HCT for myeloma, 42% of patients experienced grade III/IV toxicity; yet, the 100-day NRM rate was only 3%.
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Efficacy/Effectiveness of Auto-HCT
Studies on the effectiveness of auto-HCT in older adults have included patients harboring multiple different types of hematologic malignancies, making it difficult to precisely define clinical outcomes for any specific population of older patients. By far, auto-HCT has been used as a therapeutic option most frequently for older adults with either multiple myeloma or lymphoma. Therefore, this article reviews the effectiveness of this procedure separately for these 2 malignancies, with the realization that even within these 2 malignancies substantial heterogeneity remains.
Although randomized trials have established the efficacy of auto-HCT for multiple myeloma, these trials categorically excluded patients older than 65 years. 33, 34 No randomized trials have examined the efficacy of auto-HCT with high-dose conditioning (ie, melphalan, 200 mg/m 2 ) versus conventional therapy in older adults. Several cohort studies, however, have compared the clinical outcomes for younger and older patients who underwent auto-HCT. In these studies, younger and older patients had similar response rates, progression-free survival (PFS)/time-to-progression (TTP), and overall survival (OS), 14, 15, 18, 35 suggesting that auto-HCT may be a reasonable option for selected older adults with myeloma.
The effectiveness of auto-HCT compared with conventional or novel therapies for myeloma in older adults is also not clear. In a population-based registry study, adults aged 60 to 64 years who underwent auto-HCT had superior OS compared with patients of the same age who received only conventional chemotherapy; however, potentially confounding factors such as performance status and comorbidities were not taken into account. 36 Furthermore, the role of auto-HCT in the era of novel therapeutic agents, including the immunomodulatory agents and proteasome inhibitors, is uncertain. In a phase II trial of thalidomide, pegylated liposomal doxorubicin, and dexamethasone (ThaDD), patients ineligible for auto-HCT received 6 cycles of ThaDD plus maintenance thalidomide, whereas transplanteligible patients older than 65 years received 4 cycles of ThaDD, followed by auto-HCT with melphalan conditioning. Although patients who underwent auto-HCT had a higher complete response rate (57% vs 24%; P=.023), no significant difference in PFS ( ; MEL100) with auto-HCT. 38 In this vulnerable older population, the complete response rates (18% vs 13%) and very good partial response (VGPR) rates (43% vs 47%) were similar between MEL100 and MPT, with the MP group having significantly lower complete response (2%) and VGPR (7%) rates. However, the patients treated with MPT had an improved PFS compared with ei- 2 ), which some consider intermediate-dose as opposed to high-dose therapy. Thus, the role of auto-HCT in older adults in the era of novel therapies remains an area of active investigation.
In the context of lymphoma, the response to auto-HCT remains dependent on the subtype and stage of lymphoma, which makes studies examining the effectiveness of auto-HCT among all subtypes of lymphoma difficult to interpret. Notwithstanding this limitation, several retrospective studies of older adults undergoing auto-HCT suggest that older adults may have a slightly increased risk of relapse, and modestly decreased OS, relapse-free survival (RFS), and/or PFS, 25, 27, 28 although these findings have not been demonstrated in all studies. 17, 19, 29 Two of the largest studies showed an increased relative risk of death for older patients after auto-HCT, which was approximately 1.3 to 1.5 that found in younger adults. 27, 28 As with younger patients, adverse risk factors for OS, RFS, and PFS in older adults include poor performance status, multiple prior therapies, advanced or chemotherapy-resistant disease, high lactate dehydrogenase, and male gender. 19, 25, [27] [28] [29] 
Allo-HCT
Allo-HCT is a potentially curative treatment for hematologic malignancies, preferentially recommended to patients with high-risk features after initial chemotherapy, or after relapse. However, the use of immunosuppressive therapy and risk of graft-versushost disease leads to high rates of transplant-related mortality, especially in older adults.
Donor Selection
Donor selection is a critical element contributing to the success of allo-HCT. This is particular true in patients older than 50 to 55 years where an HLAidentical sibling is available to only 30% of the patients in need. In nearly half of cases, a matched sibling may not be available or eligible to serve as a donor. 39 For patients lacking a suitable family donor, matched unrelated donors provide an alternative option, and recent reports suggest that patients with HLA-matched related or unrelated donors have similar survival. 40 Umbilical cord blood or mismatched related (haploidentical) donors can also be used, but unlike allo-HCT from an unrelated donor, these can be associated with an increased risk of morbidity and mortality, especially in older individuals. 41 Finally, in patients older than 50 years, priority should be given to HLA-matched sibling donors, rather than younger HLA-matched unrelated donors, because the use of unrelated donors has been associated with worse relapse rates, NRM, and OS. 
Allo-HCT Conditioning
Historically, older patients (>50-55 years) with hematologic malignancies were ineligible to receive allo-HCT with myeloablative conditioning regimens. Thus, reports on the outcomes of these patients are scarce and representative of highly selected individuals. 43 The development of lower-intensity (reduced-intensity or nonmyeloablative) conditioning regimens allows allo-HCT to be performed in patients previously considered ineligible. Although most studies comparing the results of myeloablative with reduced-intensity conditioning are limited to patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), conditioning regimen intensity alone has not consistently been an independent predictor of worse outcomes. 44, 45 Nonetheless, these results must be interpreted with caution, because they represent a highly selected cohort of patients, and age should only be one of many factors considered when deciding an optimal conditioning regimen for an older patient.
Toxicity of Allo-HCT in Older Adults
Although most patients older than 50 to 55 years are ineligible to receive allo-HCT with myeloablative regimens, chronologic age alone fails to reliably predict posttransplant toxicity. In a clinical trial of adults aged 60 to 75 years, age was not associated with hospitalizations, graft-versus-host disease, or NRM. 46 Several recent studies have confirmed that advanced age (even >70 years) is not associated with higher rates of relapse or NRM, or poorer survival. 47, 48 Rather, comorbidity indices, such as the Pretransplantation Assessment of Mortality and the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI), seem to better reflect the true biologic age and are better predictors of NRM and survival. 49, 50 The HCT-CI is an adaptation of the Charlson Comorbidity Index (CCI) for the transplant setting; it assigns weights to 19 chronic conditions according to their association with 1-year mortality. The HCT-CI is a powerful predictive tool for transplant-related toxicity and mortality in older adults with high-risk myeloid malignancies. [51] [52] [53] Efficacy/Effectiveness of Allo-HCT Three large retrospective analyses have recently addressed the efficacy of allo-HCT in older patients with AML and MDS. 44, 46, 54 The median OS at 2 to 4 years ranged between 31% and 50%. Age did not impact rates of NRM, relapse rate, or rates of graftversus-host disease. For these reasons, chronologic age alone should not be the sole criterion used to determine eligibility for allo-HCT, thought it may impact the choice of conditioning regimen.
Geriatric Assessment
Cancer is a disease associated with aging, 4 and as the older population increases in the United States, more older adults will become candidates for HCT. A need exists to develop evidence-based tools to guide decisions regarding which older adults will be able to tolerate the rigorous course of HCT, and hence potentially enjoy its long-term benefit without succumbing to toxicities.
Standard pre-HCT evaluations provide a detailed assessment of many health-related factors that predict clinical outcomes. However, older patients are predisposed to a unique set of medical and social issues that may not be prevalent in younger patients but could impact outcomes. Cognitive impairment, hearing impairment, falls, and urinary incontinence are rare in younger transplant patients, but much more common in older adults. CGA may help to fill this knowledge gap. Table 2 reviews the components of CGA. CGA can identify older patients with cancer who are at increased risk for morbidity, mortality, and chemotherapy toxicity. 55, 56 A pilot study of CGA in older adults undergoing allo-HCT showed that this assessment identifies areas of vulnerability that are not apparent in a routine history and physical examination. Among 166 patients older than 50 years (16%, age >65 years) who were undergoing allo-HCT, 40% reported the need for assistance with instrumental activities of daily living (activities required to maintain independence within the com- CE munity); 51% were "pre-frail" and 25% were "frail" based on Fried frailty criteria 57 ; and 60% reported weight loss greater than 10%. The authors concluded that performing a CGA before HCT was feasible, with 73% of eligible transplant recipients completing the CGA. 58 Other studies have evaluated the impact of comorbidity, a specific focus of the CGA, on NRM and toxicity. The HCT-CI, validated among patients receiving allo-HCT, captures pretransplant comorbidities and identifies patients at increased risk for NRM. 49 Comorbidity measures are also predictive in patients undergoing auto-HCT. Among patients with multiple myeloma undergoing auto-HCT, the CCI and the HCT-CI identified patients at increased risk for toxicity and longer length of stay. 59 Further studies are needed to evaluate the combination of CGA factors that can more precisely identify patients at increased risk for toxicity and NRM, and to determine whether specific interventions can decrease this risk. Study of serial CGA throughout treatment may also help predict the short-and longterm impact of transplantation on an older adult's functional status and quality of survival. This information could provide valuable assistance in clarifying the risks and benefits of transplantation for older patients.
Conclusions
The aging of the US population and the increased incidence of hematologic malignancies with age herald an increase in the number of older adults considered for auto-HCT and allo-HCT. With the heterogeneity of aging, chronologic age alone does not consistently predict the toxicity and effectiveness of HCT. Further study will illuminate the utility of CGA in addition to standard pre-HCT evaluations for identifying older adults who are vulnerable to the toxicity of HCT, and may guide interventions to improve the care of older adults with hematologic malignancies.
